Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis

BACKGROUND AND AIM: Mucosal healing in inflammatory bowel disease (IBD) can be achieved by improvement of intestinal barrier protection. Activation of hypoxia-inducible factor (HIF) has been identified as a critical factor for barrier protection during mucosal insult and is linked with improvement i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Ram, Chaudhary, Anita R, Shah, Binita N, Jadhav, Avinash V, Zambad, Shitalkumar P, Gupta, Ramesh Chandra, Deshpande, Shailesh, Chauthaiwale, Vijay, Dutt, Chaitanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908906/
https://www.ncbi.nlm.nih.gov/pubmed/24493931
http://dx.doi.org/10.2147/CEG.S51923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908906/
https://www.ncbi.nlm.nih.gov/pubmed/24493931
http://dx.doi.org/10.2147/CEG.S51923

Ejemplares similares